

Date: August 05, 2026

**To,
BSE Limited
Department of Corporate Services
25th Floor, P J Towers,
Dalal Street, Mumbai – 400001**

BSE Scrip Code: 542934

Subject: Outcome of the meeting of Board of Directors pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In continuation to our letter date July 30, 2026 and pursuant to regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Chandra Bhagat Pharma Limited ('the Company') at its meeting held today i.e., Wednesday, August 05, 2026, has considered and approved, inter alia, following agenda items:

1. Increase in the Authorised share capital of the Company from existing Rs. 8,50,00,000/- (Rupees Eight Crores Fifty Lakhs only) divided into 85,00,000 (Eighty-Five Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each to Rs. 15,00,00,000/- (Rupees Fifteen Crore only) divided into 1,50,00,000 (One Crore Fifty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each by creation of additional Rs. 6,50,00,000/- (Rupees Six Crore Fifty Lakhs only) divided into 65,00,000 (Sixty-Five Lakhs) Equity shares of Rs. 10/- (Rupees Ten only) each subject to approval of shareholders in the ensuing general meeting of the Company;
2. Issue of up to 66,00,000 Convertible Warrants at an issue price of Rs. 44/- each including a premium of Rs. 34/- each to the promoters & non-promoters on preferential basis, subject to approval of shareholders in the ensuing general meeting of the Company;
3. Directors' Report of Company for the financial year ended on 31st March, 2026;
4. Notice of Annual General Meeting (AGM) of the Members of the Company scheduled to be held on Tuesday, September 01, 2026 at 04:00 P.M. at the Registered Office of the Company.
5. Appointment of M/s. Amit Dharmani & Associates, Company Secretaries as scrutiniser for scrutinising the voting and issuance of Scrutinizer Report to the Company.



The additional details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read with SEBI Circular HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 are enclosed as Annexure – I.

The Meeting of the Board of Directors of the Company commenced at 04:00 P.M. IST and concluded at 04:40 P.M. IST.

This is for your perusal and records.

Thanking you,

Your faithfully

Chandra Bhagat Pharma Limited

Hemant Chandravadan Bhagat
Managing Director
DIN: 00233530

ANNEXURE – I

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read with SEBI Circular HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 for Issue of Convertible Warrants on Preferential basis of Company:

S. No.	PARTICULARS	DETAILS
1.	Type of securities proposed to be issued	Convertible Warrants
2.	Type of issuance	Preferential Issue under Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
3.	Total number of securities proposed to be issued	Convertible Warrants: 66,00,000 (Sixty-Six Lakh) (Detailed list of allottees is mentioned hereunder)
4.	Total amount for which the securities will be issued	Convertible Warrants: Total amount is aggregating up to Rs. 29,04,00,000/-.
5.	Post allotment of securities- outcome of the subscription, issue price/ allotted price (in case of convertibles), number of investors In case of convertibles – intimation on conversion of securities or on the lapse of the tenure of the instrument	➤ Issue price of the Convertible Warrants of Rs. 44/- (Rupees Forty-Four only) each including a premium of Rs. 34/- (Rupees Thirty-Four only). The issue price is not lower than the floor price determined in accordance with the Regulation 164 & 166A of Chapter V of SEBI ICDR Regulations. Minimum 25% of the price of the Warrant would be payable upfront at the time of application and the balance 75% shall be payable at the time of conversion of the warrants into Equity Shares of the Company. ➤ Total number of Investors: 9 (Nine). ➤ Conversion ratio of each Convertible Warrant: 1:1 Each Warrant can be converted into 1 (One) Equity Share of the Company and conversion can be exercised at any time within a period of 18 months from the date of allotment of Warrants, in one or more tranches as the case may be and on such other terms and conditions

		as applicable. In case the investor fails to exercise the same within the stipulated period, the warrants shall lapse. The issuance of upto 66,00,000 Convertible Warrants is subject to the approval of members by way of passing special resolution at the Annual General Meeting to be held on Tuesday, September 01, 2026.
--	--	--

LIST OF INVESTORS FOR CONVERTIBLE WARRANTS:

Sr. No.	Name of the Proposed Allottees	Pre-Holding Shares	No. of Convertible Warrants to be allotted	Current Status / Category	Proposed Status / Category
1.	Hemant Chandravadan Bhagat	26,78,296	5,00,000	Promoter	Promoter
2.	Chitra Hemant Bhagat	12,33,192	5,00,000	Promoter Group	Promoter Group
3.	Pranav Hemant Bhagat	7,61,792	10,00,000	Promoter	Promoter
4.	Prachi Pranav Bhagat	4,03,600	9,50,000	Promoter Group	Promoter Group
5.	Mahesh C Bhagat	1,20,000	7,00,000	Promoter Group	Promoter Group
6.	Jay Hemant Bhagat	83,600	7,00,000	Promoter Group	Promoter Group
7.	Lopa Mahesh Bhagat	8,000	6,50,000	Promoter Group	Promoter Group
8.	Samir Ramakant Dave	-	8,00,000	Non-promoter	Non-promoter
9.	Chintan Vijay Makhecha	-	8,00,000	Non-promoter	Non-promoter